ClinicalTrials.gg
CompletedNCT05811247Updated Nov 3, 2026Results posted

Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

A Phase 3 interventional study of AD109 and Placebo in OSA, sponsored by Apnimed. Completed at 64 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Apnimed · Phase 3, Interventional, and Treatment

How we know

Updated Nov 3, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Sleep Apnea, Obstructive by Apnimed — 1 open to participants now, 1 under way, 1 of them phase 3. Sleep Apnea, Obstructive · Apnimed.

Enrollment
2nd of 13
660 · median 60
Started
2023
with 2 others
Phase 3
3 of 13
1 open now
Registered
10th of 13
by date

Among the 13 studies in Sleep Apnea, Obstructive by Apnimed, this one is the 2nd largest by enrollment, is one of 3 that started in 2023, is one of 3 in phase 3, and was the 10th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

1 of the 13 studies in Sleep Apnea, Obstructive by Apnimed is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Sleep Apnea, Obstructive by Apnimed, or all of them as a file.
02

Study summary

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.

03

Conditions studied

  • OSA

Keywords

  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years of age at the time of .
  2. PSG criteria: AHI of >5; ≤ 25% central or mixed apneas; and PLM arousal index ≤15
  3. PROMIS-Fatigue: raw score ≥17
  4. PAP intolerance or current PAP refusal.
  5. between 18.5 and 40 kg/m2 for men, or 42 kg/m2 for women, inclusive.

Exclusion criteria

Exclusion Criteria:

  1. Narcolepsy, restless leg syndrome, REM sleep behavior disorder
  2. Insomnia disorder characterized by difficulty initiating or maintaining sleep, or use within the past month of sedative-hypnotics or other medication for the purpose of treating or avoiding insomnia symptoms.
  3. Pierre Robin, Treacher Collins, or other craniofacial malformation syndrome, or grade ≥3 tonsillar hypertrophy.
  4. cardiac disease, e.g., ventricular arrhythmia, untreated or unstable coronary artery disease, cardiac failure. Stable atrial arrhythmia is allowed.
  5. Neuromuscular disorder (e.g., motor neuron disease, muscular dystrophy or myopathy, myasthenic syndrome); epilepsy; Parkinson, Alzheimer, or other neurodegenerative disease.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
660 participants (actual)

Study arms

  • Experimental
    AD109

    Drug: AD109

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugAD109

    Aroxybutynin 2.5 mg/atomoxetine 75 mg tablet, administered orally once daily at bedtime (Weeks 2-51). Week 1 run-in: aroxybutynin 2.5 mg/atomoxetine 37.5 mg tablet.

  • DrugPlacebo

    Matching placebo tablet administered orally once daily at bedtime for 51 weeks, with run-in and target dose matched to active arm packaging.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Apnea-Hypopnea Index (AHI)

    AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO2) by at least 4%.

    Time frame: 6 months

07

Results

Posted Nov 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneAD109Placebo
Started329331
Completed250274
Not completed7957
Withdrew: Adverse event127
Withdrew: Lost to follow-up2420
Withdrew: Physician decision27
Withdrew: Withdrawal by subject3319
Withdrew: Site terminated by sponsor32
Withdrew: Other/not reported52

Outcome measures

PrimaryChange From Baseline in Apnea-Hypopnea Index (AHI)

AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO2) by at least 4%.

Time frame:
6 months
Reported as:
Least squares mean · events/hr
Change From Baseline in Apnea-Hypopnea Index (AHI)
events/hrAD109Placebo
Full Analysis Set (Treatment Policy Estimand)-3.88 (-5.37 to -2.39)0.21 (-1.24 to 1.65)
While-on-Treatment population-5.83 (-7.51 to -4.15)-0.02 (-1.55 to 1.50)
Statistical analysis
  • AD109 vs Placebo · Mixed Model Repeated Measures (MMRM) · p = <0.001 · Least squares mean difference: -4.08 · 95% CI -6.14 to -2.03
  • AD109 vs Placebo · Mixed Model Repeated Measures (MMRM) · p = <0.0001 · Least squares mean difference: -5.81 · 95% CI -8.07 to -3.55

Adverse events

Collected over from enrollment until the end of follow-up, up to 53 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AD1090/328 (0%)5/328 (1.5%)220/328 (67.1%)
Placebo0/327 (0%)10/327 (3.1%)122/327 (37.3%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventAD109Placebo
Non-cardiac chest painGeneral disorders0/3281/327
Cervical radiculopathyNervous system disorders0/3281/327
DizzinessNervous system disorders0/3281/327
Ischaemic strokeNervous system disorders0/3281/327
Deep vein thrombosisVascular disorders0/3281/327
Acute myocardial infarctionCardiac disorders0/3281/327
Angina pectorisCardiac disorders0/3281/327
Atrial fibrillationCardiac disorders0/3281/327
Coronary artery diseaseCardiac disorders0/3281/327
Myocardial infarctionCardiac disorders0/3281/327
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAD109Placebo
Dry mouthGastrointestinal disorders130/32831/327
Middle insomniaPsychiatric disorders44/32813/327
NauseaGastrointestinal disorders43/3287/327
Initial insomniaPsychiatric disorders32/32812/327
Urinary hesitationRenal and urinary disorders27/3282/327
Upper respiratory tract infectionInfections and infestations19/32826/327
COVID-19Infections and infestations14/32825/327
SomnolenceNervous system disorders24/32812/327
HeadacheNervous system disorders22/32823/327
DyspepsiaGastrointestinal disorders20/3287/327

Baseline characteristics

The Full Analysis Set includes all randomized participants who were not from the terminated site 1308 and received at least 1 dose of IMP.

Age, Continuous
Age, Continuous(years)AD109PlaceboTotal
Mean57.2 ± 10.2657.4 ± 10.7257.3 ± 10.49
Sex: Female, Male
Sex: Female, Male(Participants)AD109PlaceboTotal
Female160138298
Male164188352
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AD109PlaceboTotal
American Indian or Alaska Native5510
Asian11920
Native Hawaiian or Other Pacific Islander336
Black or African American5853111
White238246484
More than one race347
Unknown or Not Reported6612
Baseline AHI4 group
Baseline AHI4 group(Participants)AD109PlaceboTotal
<15119125244
15 - 30109104213
>309697193
Baseline AHI4
Baseline AHI4(events/hr)AD109PlaceboTotal
Mean24.03 ± 16.69224.69 ± 18.73524.36 ± 17.736
08

Study locations

64 sites
  • Sleep Disorders Center of Alabama
    Birmingham, Alabama 35213, United States
  • Chandler Clinical Trials
    Chandler, Arizona 85224, United States
  • Preferred Research Partners, Inc.
    Little Rock, Arkansas 72211, United States
  • Orange County Research Institute
    Anaheim, California 92801, United States
  • Marvel Clinical Research, LLC
    Huntington Beach, California 92647, United States
  • CenExel CNS
    Los Alamitos, California 90720, United States
  • Santa Monica Clinical Trials
    Los Angeles, California 90025, United States
  • Empire Clinical Research
    Pomona, California 91767, United States
  • Pacific Research Network
    San Diego, California 92103, United States
  • SDS Clinical Trials Inc.
    Santa Ana, California 92705, United States
  • Alpine Clinical Research Center
    Boulder, Colorado 80301, United States
  • Mountain View Clinical Research, Inc.
    Denver, Colorado 80209, United States
  • Nuvance Health
    Norwalk, Connecticut 06850, United States
  • Teradan Clinical trials LLC
    Brandon, Florida 33511, United States
  • St. Francis Medical Institute
    Clearwater, Florida 33765, United States
  • Nouvelle Clinical Research
    Cutler Bay, Florida 33189, United States
  • Arrow Clinical Trials
    Daytona Beach, Florida 32117, United States
  • Cenexel Research Centers of America - Hollywood
    Hollywood, Florida 33024, United States
  • Ivetmar Medical Group LLC
    Miami, Florida 33155, United States
  • PharmaDev Clinical Research Institute, LLC
    Miami, Florida 33176, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Palm Beach Research ClinEdge-PPDS
    West Palm Beach, Florida 33409, United States
  • Clinical Site Partners, LLC dba Flourish Research
    Winter Park, Florida 32789, United States
  • NeuroTrials Research
    Atlanta, Georgia 30328, United States
  • CenExel iResearch
    Decatur, Georgia 30030, United States
  • Sleep Practitioners, LLC
    Macon, Georgia 31210, United States
  • Centricity Research Rincon Pulmonology
    Rincon, Georgia 31326, United States
  • Medster Research
    Valdosta, Georgia 31605, United States
  • Chicago Research Center Inc
    Chicago, Illinois 60634, United States
  • Sleep Disorders Centers of the Mid-Atlantic
    Glen Burnie, Maryland 21061, United States
  • Velocity Clinical Research
    Rockville, Maryland 20854, United States
  • Neurocare, Inc
    Newton, Massachusetts 02459, United States
  • Infinity Medical Research
    North Dartmouth, Massachusetts 02747, United States
  • Baystate Medical Center (BMC) - Baystate Sleep Medicine
    Springfield, Massachusetts 01199, United States
  • Western Michigan University Homer Stryker M.D. School of Medicine
    Kalamazoo, Michigan 49008, United States
  • Henry Ford Health (Sleep Research Department)
    Novi, Michigan 48377, United States
  • Clinical Neurophysiology Services
    Sterling Heights, Michigan 48314, United States
  • St Lukes Hospital
    Chesterfield, Missouri 63017, United States
  • Healthcare Research Network
    Hazelwood, Missouri 63042, United States
  • Clayton Sleep Institute
    St Louis, Missouri 63123, United States
  • Great Plains Health
    North Platte, Nebraska 69101, United States
  • Henderson Clinical Trials
    Henderson, Nevada 89052, United States
  • Clinilabs, Inc
    Eatontown, New Jersey 07724, United States
  • Maimonides Sleep Arts and Sciences
    Albuquerque, New Mexico 87107, United States
  • Northwell Health Physician Partners
    New Hyde Park, New York 11042, United States
  • Research Carolina Elite
    Denver, North Carolina 28037, United States
  • Clinical Research of Gastonia
    Gastonia, North Carolina 28054, United States
  • Advanced Respiratory and Sleep Medicine, LLC
    Huntersville, North Carolina 28078, United States
  • Coastal Carolina Health Care
    New Bern, North Carolina 28562, United States
  • Meridian Clinical Research
    Raleigh, North Carolina 27607, United States
  • NeuroScience Research Center, LLC
    Canton, Ohio 44718, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Sleep Management Institute
    Cincinnati, Ohio 45245, United States
  • Ohio Sleep Medicine Institute
    Dublin, Ohio 43017, United States
  • Northwest Research Center
    Portland, Oregon 97202, United States
  • Brian Abaluck, LLC
    Malvern, Pennsylvania 19355, United States
  • UPMC Comprehensive Lung Center - Sleep Medicine
    Pittsburgh, Pennsylvania 15213, United States
  • Lowcountry Lung and Critical Care
    Charleston, South Carolina 29406, United States
  • Velocity Clinical Research - Greenville
    Greenville, South Carolina 29615, United States
  • Clinical Neuroscience Solutions - Memphis
    Memphis, Tennessee 38119, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • Central Texas Neurology Consultants, PA
    Round Rock, Texas 78681, United States
  • Sleep Therapy Research Center
    San Antonio, Texas 78229, United States
  • Sleep Disorders Centers of the Mid-Atlantic
    Vienna, Virginia 22182, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in May 2025, 20 months.

Results were first posted in Nov 2026, 1 year 5 months after primary completion.

Of 27 phase 3 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 32. This study's 20 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2023
First posted
Apr 13, 2023
StartActual
Aug 28, 2023
Primary completionActual
May 7, 2025
CompletionActual
May 7, 2025
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 3, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange fromFrom Baseline in Apnea-Hypopnea Index (AHI)Time frame: 6 months
Nov 3, 2026
Documents
Show all 1 update
  1. Nov 3, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange fromFrom Baseline in Apnea-Hypopnea Index (AHI)Time frame: 6 months
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05811247
Lead sponsor
Apnimed
Responsible party
Sponsor
First posted
Apr 13, 2023
Start date
Aug 28, 2023
Primary completion
May 7, 2025
Completion
May 7, 2025
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AD109

Start the discussion